In 142 adults with primary membranous nephropathy, obinutuzumab gave more complete remission at week 104 than tacrolimus (37% vs 6%; difference 31 points, 95% CI 18–44). No significant effect on sustained eGFR decline; grade ≥3 adverse events 22% vs 19%.
RCTn = 142
Fervenza et al. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy